While CD39 expression on T cells has traditionally been described a marker of exhaustion and dysfunctionality, emerging patient reports show that CD39-expressing T cells are enriched in solid tumours, where they are shown to be preferentially tumour antigen-specific (59–61). Here, ENTPD1 is linked to neoplasm.